Overview

Pharmacokinetic Study With Repeated Doses of Stalevo

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.
Phase:
Phase 1
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Carbidopa
Entacapone
Levodopa